Conference Overview

With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug. However, evidences suggest though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use.  Pharmacovigilance brief the potential implications of such trends on the evolution of the science. 

However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc. 


The Pharmacovigilance World 2022 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and how it contributes to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field. Our Pharmacovigilance conferences are known for bringing the world-class leaders together to connect, learn and network. The conference will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.


It gives us a great pleasure in welcoming you to the Pharmacovigilance World 2022 conference.

Conference Streams Include



Global PV & Methodologies

Data management & Analytics in PV

PV Automation, AI & Machine Learning

Safety Signals & Management

Pharmacovigilance Regulations


Patient Centric Drug Safety


Quality &

Pharmacovigilance Outsourcing

Medical Devices Safety

Adverse Drug Reactions




  • Pharmacovigilance and globalization
  • Pharmacovigilance in a pandemic world
  • Women and child health care medicines and pharmacovigilance
  • Patient-centric approaches in PV
  • Pharmacovigilance legislation and regulations
  • Harmonization and pharmacovigilance
  • Advanced therapeutic techniques and pharmacovigilance
  • Pharmacovigilance and data management and eudravigilance
  • Post-marketing surveillance in pharmacovigilance
  • PV regulations and challenges
  • Benefit-risk management strategies
  • Risk management and minimization
  • Risk Evaluation and Mitigation
  • Adverse drug reactions reporting
  • Signal detection and post authorization safety
  • Good Pharmacovigilance Practices
  • Innovative approaches to drug safety
  • Strategies to improve PV
  • Real World Evidence in PV
  • Big data and AI in pharmacovigilance
  • Pharmacovigilance Workflows with AI & Automation
  • Other emerging technologies in PV





CEOs, CTOs, CIOs, Presidents, Vice Presidents, Directors, Heads & Managers, Scientific Advisors, Consultants and professionals who work for pharmaceutical, biotechnology & devices industries, CROs and service providers involved in Pharmacovigilance and Drug safety.

Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of

  • Pharmacovigilance
  • Safety & Risk management
  • Drug safety
  • PV Compliance
  • Safety Surveillance
  • Medical Affairs
  • Regulatory Affairs
  • Inspection and Audit
  • Pharmacoepidemiology
  • Post-market studies
  • Medical product safety assessment
  • Drug Research & Development
  • Clinical Pharmacology
  • Medical information
  • Contract outsourcing service providers
  • Health outcomes
  • Sales and Marketing





pharmaceutical companies



There are plenty of opportunities to position yourself as a thought leader & showcase your company.

For enquiries on speaker opportunities please e-mail to [email protected]

Tuesday - 22nd November 2022 (Time Zone - GMT)

  • 09:30
  • Welcome Address & Platform Orientation - Orientation will focus on how to access and navigate the virtual conference platform for Live Sessions & Interactive Networking

  • 09:40
  • Chairperson’s opening remarks

  • 09:50
  • Assessing the Quality of ICSRs & the Impact on causality assessment and signal evaluation

    Maria De Los Angeles Hernandez Loli

    Maria De Los Angeles Hernandez Loli Patient Safety Lead Cluster Ecuador - Peru
    Boehringer Ingelheim

Drug Safety Strategies & Pharmacovigilance

  • 10:15
  • Women and child health care medicines and pharmacovigilance

    Carla Valeria Massironi

    Carla Valeria Massironi CHC Country Safety Head

  • 10:35
  • Panel Discussion - An Integrated care: Effective Implementation of vigilances systems

    • Separated vigilance systems can lead to the emergence of divergence in terms, definitions, variety of reporting forms and methods and the build of specific databases where cross analysis is no more possible.
    • To be more proactive and innovative in PV and to ensure that emerging problems are promptly recognized and solutions are effectively communicated
    • This integrated approach is very useful, especially for emerging countries to strengthen regulatory processes and to promote high standards of product vigilance for the protection of the health and safety of Citizens

  • 11:05
  • Drug Safety Evaluation Strategies

    Nibha Mishra

    Nibha Mishra Senior Scientist

  • 11:25
  • ICH in Brazil: New PV Regulation following Incorporation of ICH Guidelines

    Raphael Elmadjian Pareschi

    Raphael Elmadjian Pareschi Pharmacovigilance Associate Director

Safety Signals & Risk Management

  • 11:45
  • Innovative techniques and strategies in signal detection

    • The lacunae in existing technique
    • New strategies that have been implemented recently
    • How have implementation of new strategies benefited signal detection studies

    Booked for Aris Global (Platinum Sponsor) 

  • 12:05
  • An industrial perspective: Post-marketing Signal Detection and management

    • Present Drug safety signal detection systems and tools and what do they lack
    • Emerging techniques and tools in detection and management of signals
    • Sources for identifying safety signals

    Ajinkya Inamdar

    Ajinkya Inamdar Director, Vaccines Global Safety Strategy and Risk Management
    Janssen Pharmaceutical

  • 12:30
  • Virtual Luncheon & Networking - Visit Exhibitor Booths & Network with your peers in our Lounge (Face to Face Video Chats)



  • 13:00
  • Risk management in Mexico: challenges and opportunities

    Rodrigo Ruiz

    Rodrigo Ruiz Senior Manager, Patient Safety
    Bristol-Myers Squibb

  • 13:25
  • Risk minimization and management

    • Assessment with comprehensive data quality
    • Compliant safety system (GxP compliant, inspection-ready system)
    • Safety signals, effective trials, strategic risk assessment decisions

    Klaudija Marijanovic Barac

    Klaudija Marijanovic Barac EU & UK QPPV deputy
    Teva Pharmaceuticals

  • 13:50
  • Review of aRMM effectiveness measures in Europe

    Robert Massouh

    Robert Massouh Director - Risk Management Product Lead

  • 14:15
  • Signal Detection and Communications in PV

    Eman Gomaa

    Eman Gomaa MEA PV Hub Lead

Quality Assurance and Regulatory Compliance

  • 14:40
  • Key steps for establishing and maintaining compliance with all applicable internal and external requirements and regulations

    Sam Bovonsombat

    Sam Bovonsombat Associate Director, Global Quality Management

  • 15:05
  • What are the key steps for establishing and maintaining compliance with all applicable internal and external requirements and regulations


    For sponsorship opportunities please contact: [email protected] or call +44 (0) 207 096 0786

  • 15:30
  • Visit Virtual Exhibitor Booths/Speed Networking at our Exclusive Lounge (Face to Face Video chat with Exhibitors and other attendees)



  • 15:50
  • Pharmacovigilance Audit Inspection & Quality systems

    Valentina Mancini

    Valentina Mancini Director Pharmacovigilance, EU and UK QPPV

  • 16:15
  • Pharmacovigilance System: Audit & Inspection Readiness

    • Sales, information and knowledge of consumers
    • Awareness, generic names, reduction of medication errors in private clinics
    • Industrial association

    Raj K Bhogal

    Raj K Bhogal Senior Director, R&D Audits & Inspections
    Jazz Pharmaceuticals

Advanced therapy medicinal products (ATMPs) and PV

  • 16:40
  • Advanced therapeutic techniques and pharmacovigilance

    • Advanced therapeutic techniques and pharmacovigilance
    • Challenges related with monitoring and safety
    • Benefit-risk assessment of ATMP

    Retesh Kumar

    Retesh Kumar Director, Global Pharmacovigilance, Therapeutic Area Lead- Cardio Renal
    Otsuka Pharmaceutical Companies (U.S)

  • 17:05
  • Hepatotoxicity of new therapies

    Ester Pena - Van Leeuwen

    Ester Pena - Van Leeuwen Ass Global Medical Safety Director
    Astellas Pharma Europe

Outsourcing & Vendor Management

  • 17:30
  • Developing Value-Based Partnerships

    • Establishing a clear understanding of the goals and objectives of the partnership
    • Defining the roles and responsibilities of each partner
    • Negotiating and formalizing agreements between partners
    • Monitoring and evaluating the partnership performance on an ongoing basis

    Cinthya Galicia Quintanar

    Cinthya Galicia Quintanar Senior Manager, Country Safety Lead

  • 17:55
  • Build Effective Metrics for Vendor Oversight

    Julia Appelskog

    Julia Appelskog EU QPPV, Head of EU QPPV Office

  • 18:20
  • Chairperson’s closing remarks

  • 18:30
  • Virtual Networking - Catch-up with your peers in social lounge

Wednesday - 23rd November 2022 (Time Zone - GMT)

  • 09:30
  • Welcome Address & Platform Orientation - Orientation will focus on how to access and navigate the virtual conference platform for Live Sessions & Interactive Networking

  • 09:40
  • Chairperson’s opening remarks

  • 09:50
  • Improving the quality of your adverse event reporting system (Topic TBC)

    Santiago Schiaffino

    Santiago Schiaffino Head of PV Systems and Standards / Deputy EUQPPV
    Boehringer Ingelheim

  • 10:15
  • Service provider Presentation


    For sponsorship opportunities please contact: [email protected] or call +44 (0) 207 096 0786

Automation, AI & Data Management

  • 10:35
  • Impact of AI & Machine learning on Pharmacovigilance and Drug Safety

    • Ever expanding data and its safety
    • Importance and application of AI
    • Improving speed, accuracy and reliability using AI

    Robert Di Giovanni

    Robert Di Giovanni Global Project Safety Lead

  • 11:00
  • Automation and pharmacovigilance: identifying risk factors for AEs

    Michael Von Forstner

    Michael Von Forstner Global Head of Clinical Safety and Pharmacovigilance

  • 11:25
  • New developments in Safety Data Signal Detection and Evaluation

    Marianna Trani

    Marianna Trani Safety Risk Lead

  • 11:50
  • Improving patient involvement and wearables

    • Role of internet/ communication techniques, advertisement
    • Post-market surveillance of devices
    • Therapeutic good administration
    • Safety management

    Yvonne Nanciu

    Yvonne Nanciu Country Head Pharmacovigilance Germany

  • 12:15
  • PSMF – Pharmacovigilance system master file

    • PSMF summary design, role of QPPV and managing audits.
    • Responsibilities of stakeholders.
    • Accessibility of PSMF and Transparency and ensuring compliance
    • Challenges in the managing data collection, audit information and documenting changes in logbooks, transferring information to license partners or third parties

  • 12:35
  • Virtual Luncheon & Networking - Visit Exhibitor Booths & Network with your peers in our Lounge (Face to Face Video Chats)



  • 13:05
  • Leveraging Data Analytics to predict risks to a Pharmacovigilance System

    Minhaj Obeidullah

    Minhaj Obeidullah Head Compliance & Risk Management

  • 13:30
  • Artificial Intelligence in Medical Device


    Booked for Gavion Technologies

  • 13:55
  • Pharmacoepidemiology and Real-World Evidence (RWE) generation

  • 14:20
  • Panel Discussion – The future of pharmacovigilance: How technology will change the way we monitor drugs

    • The future of pharmacovigilance will be more automated
    • AI will play a big role in data management and analysis
    • The use of technology will increase speed and accuracy

    Yvonne Nanciu

    Yvonne Nanciu Country Head Pharmacovigilance Germany

Case Processing & Patient Centric Approach

  • 14:50
  • Importance of Quality Case Processing in Pharmacovigilance

    Laura Arce Mora

    Laura Arce Mora Country Safety Lead

  • 15:15
  • AI & Machine Learning for Automated Case Processing in Pharmacovigilance

  • 15:40
  • Visit Virtual Exhibitor Booths/Speed Networking at our Exclusive Lounge (Face to Face Video chat with Exhibitors and other attendees)



  • 16:00
  • Partnership arrangements to speed up case processing times, improve data quality, and reduce costs are an essential part of ensuring the safety of drugs and protecting patients' health

    Victoria Bartasek

    Victoria Bartasek Senior Associate Director, Global Pharmacovigilance Operations
    Boehringer Ingelheim

  • 16:25
  • Designing a Patient Centred Pharmacovigilance System

  • 16:50
  • Chairperson’s closing remarks & End of Conference

What do the Pass Include

  •  C-Suite keynote sessions & Panel Discussions
  •  Full 2-day live event Access
  •  Interactive live Video chat
  •  Interactive Social lounge with individual tables for discussions & Exchange of Information
  •  Q&A Session and polling
  •  Messaging meetings and networking with Industry Experts and Peers
  •  Access to Virtual expo (including videos, reports and articles from solution providers),
  •  Receiving Handouts
  •  On demand event recordings until 1 month
  •  Certificate for attending

Delegate Registration

Corvus Global Events recognises the value of learning in teams. There's so much great content!!!

Bring your team and get an extra discount. There are special group packages available. Please email to [email protected]for more details.

register now


Partnerships typically involve an exchange of value and frequently include online content, PR, advertising, online & event branding.

For enquiries please e-mail to [email protected]



Our interactive platform has many rich features and they are a great experience for the users with Networking Video Chat, Polling, Raise Hand, Virtual Exhibitor booths with waiting room/tables, Q&A Sessions with industry experts, virtual chat, Peer to Peer connect at Social Lounge and Handout Bag

Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now